FIBROMAS UTERINOS: CONCEPTOS ACTUALES

Konstantinos Tserotas

Enviado octubre 12, 2024

Publicado 2026-04-06

Artículos de Investigación

Vol. 15 Núm. 2 (2002): Revista Médico Científica

FIBROMAS UTERINOS: CONCEPTOS ACTUALES

Konstantinos Tserotas⁺⁻

PDF

Citación:

DOI: ND

Publicado: 2026-04-06

Derechos de autor 2024 Revista médico científica

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.

Resumen

Los fibromas uterinos son tumores benignos que aparecen con frecuencia en mujeres de edad fértil. Muchas veces son asintomáticos pero pueden producir sangrados irregulares, dolor pélvico e infertilidad. Si bien su fisiopatología no es conocida tenemos varios tratamientos tanto quirúrgicos como médicos para su manejo. Todavía la investigación no nos brinda la respuesta final para su prevención y tratamiento , mientras tanto le ofrecemos a nuestras pacientes medidas paliativas.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Buttram VC, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981; 36:433-45.
Stewart EA. Uterine Fibroids. Lancet 2001; 357:293-8.
Kjerulff KH, Langenberg P, Seidman JD, Stolley PD, Guzinski GM. Uterine leiomyomas: racial differences in severity, symptoms and age at diagnosis. J Reprod Med 1996; 41:483-90.
Parazzini F, La Vecchia C, Negri E, Cecchetti G, Fedele L. Epidemiologic characteristics of women with uterine fibroids: a case-control study. Obstet Gynecol 1988; 72:853-7.
Schwartz SM. Epidemiology of uterine leiomyomata. Clin Obstet Gynecol 2001; 44:316-26.
Brandon DD, Erickson TE, Keenan EJ. Estrogen receptor gene expression in human uterine leiomyomas. J Clin Endocrinol Metab 1995; 80:1876-81.
Sumitami H, Shozu M, Segawa T. In situ estrogen synthesized by aromatase P450 in uterine leiomyomata cells promotes cell growth probably via an autocrine/paracrine mechanism. Endocrinology 2000; 141:3852-61.
Nowak RA. Identification of new therapies for leiomyomas: What in vitro studies can tell us. Clin Obstet Gynecol 2001; 44:327-34.
Gross KL, Morton CC. Genetics and the development of fibroids. Clin Obstet Gynecol 2001; 44:335-49.
Fedele L, Parazzini F, Luchini L, Mezzopane R, Tozzi L, Villa L. Recurrence of fibroids after myomectomy: a transvaginal ultrasonographic study. Hum Reprod 1995; 10:1795-6.
Garnet JD. Uterine rupture during pregnancy. Obstet Gynecol 1964; 23:898-905.
Ubaldi F, Tourmaye H, Camus M, Van der Pas H, Gepts E, Devroey P. Fertility after hysteroscopic myomectomy. Hum Reprod Update 1995; 1:81-90.
Arcangeli S, Pasquarette MM. Gravid uterine rupture after myolysis. Obstet Gynecol 1997; 89:857.
Derman SG, Rehnstrom J, Neuwirth RS. The long-term effectiveness of hysteroscopic treatment of menorrhagia and leiomyomas. Obstet Gynecol 1991; 77:591-4.
Goodwin SC, Wong GC. Uterine artery embolization for uterine fibroids: a radiologist's perspective. Clin Obstet Gynecol 2001; 44(6):412-24.
Chavez NF, Stewart EA. Medical treatment of uterine fibroids. Clin Obstet Gynecol 2001; 44:372-84.
Friedman AJ, Daly M, Juneau-Norcross M, Gleason R, Rein MS, LeBoff M. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin "add-back" for 2 years. Hum Reprod 1994; 9:1618-25.
Palomba S, Affinito P, Tommaselli GA. A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata. Fertil Steril 1998; 70:111-8.
Coutinho EM. Treatment of large fibroids with high doses of gestrinone. Gynecol Obstet Invest 1990; 30:44-7.
Reissmann T, Felderbaum R, Diedrich K. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod 1995; 10:1974-81.
Murphy AA, Kettel LM, Morales AJ. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 1993; 76:513-7.
Walker CL, Burroughs KD, Davis B. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyomas. J Soc Gynecol Investig 2000; 7:249-56.
Stewart EA, Nowak RA. Leiomyomata-related bleeding: a classic hypothesis updated for the molecular era. Hum Reprod Update 1996; 2:295-306.
Christman GM, McCarthy JF. Gene therapy and uterine leiomyomas. Clin Obstet Gynecol 2001; 44:425-35.

Palabras clave

PDF

Resumen visto - 3 veces
PDF descargado - 0

Licencia

Content Top

[1] Buttram VC, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981; 36:433-45.

[2] Stewart EA. Uterine Fibroids. Lancet 2001; 357:293-8.

[3] Kjerulff KH, Langenberg P, Seidman JD, Stolley PD, Guzinski GM. Uterine leiomyomas: racial differences in severity, symptoms and age at diagnosis. J Reprod Med 1996; 41:483-90.

[4] Parazzini F, La Vecchia C, Negri E, Cecchetti G, Fedele L. Epidemiologic characteristics of women with uterine fibroids: a case-control study. Obstet Gynecol 1988; 72:853-7.

[5] Schwartz SM. Epidemiology of uterine leiomyomata. Clin Obstet Gynecol 2001; 44:316-26.

[6] Brandon DD, Erickson TE, Keenan EJ. Estrogen receptor gene expression in human uterine leiomyomas. J Clin Endocrinol Metab 1995; 80:1876-81.

[7] Sumitami H, Shozu M, Segawa T. In situ estrogen synthesized by aromatase P450 in uterine leiomyomata cells promotes cell growth probably via an autocrine/paracrine mechanism. Endocrinology 2000; 141:3852-61.

[8] Nowak RA. Identification of new therapies for leiomyomas: What in vitro studies can tell us. Clin Obstet Gynecol 2001; 44:327-34.

[9] Gross KL, Morton CC. Genetics and the development of fibroids. Clin Obstet Gynecol 2001; 44:335-49.

[10] Fedele L, Parazzini F, Luchini L, Mezzopane R, Tozzi L, Villa L. Recurrence of fibroids after myomectomy: a transvaginal ultrasonographic study. Hum Reprod 1995; 10:1795-6.

[11] Garnet JD. Uterine rupture during pregnancy. Obstet Gynecol 1964; 23:898-905.

[12] Ubaldi F, Tourmaye H, Camus M, Van der Pas H, Gepts E, Devroey P. Fertility after hysteroscopic myomectomy. Hum Reprod Update 1995; 1:81-90.

[13] Arcangeli S, Pasquarette MM. Gravid uterine rupture after myolysis. Obstet Gynecol 1997; 89:857.

[14] Derman SG, Rehnstrom J, Neuwirth RS. The long-term effectiveness of hysteroscopic treatment of menorrhagia and leiomyomas. Obstet Gynecol 1991; 77:591-4.

[15] Goodwin SC, Wong GC. Uterine artery embolization for uterine fibroids: a radiologist's perspective. Clin Obstet Gynecol 2001; 44(6):412-24.

[16] Chavez NF, Stewart EA. Medical treatment of uterine fibroids. Clin Obstet Gynecol 2001; 44:372-84.

[17] Friedman AJ, Daly M, Juneau-Norcross M, Gleason R, Rein MS, LeBoff M. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin "add-back" for 2 years. Hum Reprod 1994; 9:1618-25.

[18] Palomba S, Affinito P, Tommaselli GA. A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata. Fertil Steril 1998; 70:111-8.

[19] Coutinho EM. Treatment of large fibroids with high doses of gestrinone. Gynecol Obstet Invest 1990; 30:44-7.

[20] Reissmann T, Felderbaum R, Diedrich K. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod 1995; 10:1974-81.

[21] Murphy AA, Kettel LM, Morales AJ. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 1993; 76:513-7.

[22] Walker CL, Burroughs KD, Davis B. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyomas. J Soc Gynecol Investig 2000; 7:249-56.

[23] Stewart EA, Nowak RA. Leiomyomata-related bleeding: a classic hypothesis updated for the molecular era. Hum Reprod Update 1996; 2:295-306.

[24] Christman GM, McCarthy JF. Gene therapy and uterine leiomyomas. Clin Obstet Gynecol 2001; 44:425-35.

Imagen de portada

Resumen

Descargas

Citas

Palabras clave

Licencia